尤瑞克林治疗急性脑梗死临床疗效分析

杜继慧



尤瑞克林治疗急性脑梗死临床疗效分析

杜继慧

【摘要】目的 观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法 将86例急性脑梗死患者随机分为对照组和尤瑞克林治疗组，两组均给予抗血小板聚集、控制血压等常规治疗，治疗组加用0．9%生理盐水100 ml+尤瑞克林0．15 U静脉滴注，每日1次，连续治疗14 d。观察两组患者治疗前及治疗14 d后神经功能缺损程度、临床疗效及生化指标变化。结果 经尤瑞克林治疗14 d后，治疗组神经功能恢复优于对照组，两组间神经功能评分差异有统计学意义（P＜0．05）；治疗组治疗前后实验室指标变化差异无统计学意义（P＞0．05）。结论 尤瑞克林治疗急性脑梗死安全、有效。

【关键词】急性脑梗死；尤瑞克林，疗效

Objective To investigate the efficacy and security of Urinary Kallikrein in patients with acute cerebral infarction（ACI）． Methods 86 ACI patients were randomly divided into the control group and the Urinary Kallikrein group． Both groups of patients were received conventional therapy，such as anti-platelet aggregation and control of blood pressure． Besides the conventional therapy，the patients in the Urinary Kallikrein group also received Urinary Kallikrein treatment for 14 days． The patients were evaluated by the neurologic function score，therapeutic efficiency and biochemical indicator before and after 14 days therapy． Results The neurologic functional recovery of the Urinary Kallikrein group was obviously surpassed than that of the control group． There was significantly different between the two groups after 14 days therapy in the neurologic function score and the total efficiency（P ＜0．05）． In the Urinary Kallikrein group，there was not significantly different between before and after 14 days therapy in biochemical indicator（P＞0．05）． Conclusion Urinary Kallikrein treatment on acute cerebral infarction was safe and effective．

【Key words】Acute cerebral infarction，Urinary kallikrein，Efficacy

急性脑梗死是一种严重威胁人类健康的疾病，发病率高、病残率高、死亡率高，给家庭及社会带来沉重的负担。国内临床常用改善脑血循环的治疗药物包括：抗凝药物、降纤药物、扩容药物、抗血小板药物及改善微循环药物，虽然这些药物机制有改善血液循环的作用，但不能直接恢复再灌注。尤瑞克林即人尿激肽原酶，来自于健康人的尿液中提取的一种糖蛋白，研究显示尤瑞克林具有改善脑动脉循环的作用［1］，对于急性脑梗死的治疗效果良好。本项研究初步探讨使用尤瑞克林治疗急性脑梗死的疗效及安全性。

1 对象与方法

1.1 对象

2015年7月～2016年1月连续收集我院神经内科收治的急性脑梗死患者86例，急性脑梗死诊断标准：（1）急性起病；（2）局灶神经功能缺损（一侧面部或肢体无力或麻木，语音障碍等），少数为全面神经功能缺损；……